Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib vs Investigator Selected TKI in Newly Diagnosed Ph+ CML-CP
NCT04971226Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2021
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of asciminib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Major Molecular Response at Week 48. Started Oct 2021; status: active, not recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04971226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971226.